Is Mechanical Clot Removal or Disruption a Cost-Effective Treatment for Acute Stroke?

References

1. 1.↵
   1. Smith WS,
   2. Sung G,
   3. Starkman S,
   4. et al

   . Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432–38. Epub 2005 Jun 16

   Abstract/FREE Full Text
2. 2.↵
   1. Smith WS

   . Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke: results of the Multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol 2006;27:1177–82

   Abstract/FREE Full Text
3. 3.↵
   1. Bose A,
   2. Henkes H,
   3. Alfke K,
   4. et al

   . The Penumbra system: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol 2008;29:1409–13

   Abstract/FREE Full Text
4. 4.↵
   Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–87

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Fagan SC,
   2. Morgenstern LB,
   3. Petitta A,
   4. et al

   . Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke: NINDS rt-PA Stroke Study Group. Neurology 1998;50:883–90

   Abstract/FREE Full Text
6. 6.↵
   1. Patil CG,
   2. Long EF,
   3. Lansberg MG

   . Cost-effectiveness analysis of mechanical thrombectomy in acute ischemic stroke. J Neurosurg 2009;110:508–13

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Hills NK,
   2. Johnston SC

   . Why are eligible thrombolysis candidates left untreated? Am J Prev Med 2006;31:S210–16

   CrossRefPubMed
8. 8.↵
   1. Hacke W,
   2. Kaste M,
   3. Bluhmki E,
   4. et al

   . Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–29

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Rha JH,
   2. Saver JL

   . The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007;38:967–73

   Abstract/FREE Full Text
10. 10.↵
    1. Flint AC,
    2. Duckwiler GR,
    3. Budzik RF,
    4. et al

    . Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and Multi MERCI Part I trials. Stroke 2007;38:1274–80. Epub 2007 Mar 1

    Abstract/FREE Full Text
11. 11.↵
    1. Barnwell SL,
    2. Clark WM,
    3. Nguyen TT,
    4. et al

    . Safety and efficacy of delayed intra-arterial urokinase therapy with mechanical clot disruption for thromboembolic stroke. AJNR Am J Neuroradiol 1994;15:1817–22

    Abstract/FREE Full Text
12. 12.↵
    1. Smith WS,
    2. Sung G,
    3. Saver J,
    4. et al

    . Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008;39:1205–12

    Abstract/FREE Full Text
13. 13.↵
    1. Gold MR,
    2. Siegel JE,
    3. Russell LB,
    4. et al

    . Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996
14. 14.↵
    1. Adams HP Jr.,
    2. del Zoppo G,
    3. Alberts MJ,
    4. et al

    . Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups—the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655–711. Epub 2007 Apr 12

    Abstract/FREE Full Text
15. 15.
    1. Furlan A,
    2. Higashida R,
    3. Wechsler L,
    4. et al

    . Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study—a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003–11

    CrossRefPubMedWeb of Science
16. 16.
    Department of Health and Human Services. Centers for Medicare & Medicaid Services. Changes to the hospital inpatient prospective payment systems and fiscal year 2009 rates. Federal Register 73:48433–9084. http://www.access.gpo.gov/su_docs/fedreg/a080819c.html. Published August 19, 2008. Accessed October 12, 2009
17. 17.↵
    1. Kent D,
    2. Kuntz KM,
    3. Patel MR,
    4. et al

    . Perioperative imaging strategies for carotid endarterectomy: an analysis of morbidity and cost-effectiveness in symptomatic patients. JAMA 1995;274:888–94

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Eckman MH,
    2. Rosand J,
    3. Knudsen KA,
    4. et al

    . Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003;34:1710–16

    Abstract/FREE Full Text
19. 19.
    1. Earnshaw SR,
    2. Joshi AV,
    3. Wilson MR,
    4. et al

    . Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke 2006;37:2751–58. Epub 2006 Sep 28

    Abstract/FREE Full Text
20. 20.↵
    1. Laupacis A,
    2. Feeny D,
    3. Detsky AS,
    4. et al

    . How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473–81

    Abstract
21. 21.↵
    1. Yasaka M,
    2. O'Keefe GJ,
    3. Chambers BR,
    4. et al

    . Streptokinase in acute stroke: effect on reperfusion and recanalization—Australian Streptokinase Trial study group. Neurology 1998;50:626–32

    Abstract/FREE Full Text
22. 22.↵
    1. Kuntz KM,
    2. Kent KC

    . Is carotid endarterectomy cost-effective? An analysis of symptomatic and asymptomatic patients. Circulation 1996;94:II194–198

    PubMed
23. 23.↵
    1. Johnston SC,
    2. Gress DR,
    3. Kahn JG

    . Which unruptured cerebral aneurysms should be treated? A cost-utility analysis. Neurology 1999;52:1806–15

    Abstract/FREE Full Text
24. 24.↵
    1. Mori E,
    2. Yoneda Y,
    3. Tabuchi M,
    4. et al

    . Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;42:976–82

    Abstract/FREE Full Text
25. 25.↵
    1. del Zoppo GJ,
    2. Higashida RT,
    3. Furlan AJ,
    4. et al

    . PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke—PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998;29:4–11

    Abstract/FREE Full Text
26. 26.↵
    1. Molina CA,
    2. Montaner J,
    3. Abilleira S,
    4. et al

    . Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke 2001;32:2821–27

    Abstract/FREE Full Text
27. 27.↵
    1. Cintas P,
    2. Le Traon AP,
    3. Larrue V

    . High rate of recanalization of middle cerebral artery occlusion during 2-MHz transcranial color-coded Doppler continuous monitoring without thrombolytic drug. Stroke 2002;33:626–28

    Abstract/FREE Full Text
28. 28.↵
    1. Rother J,
    2. Schellinger PD,
    3. Gass A,
    4. et al

    . Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke 2002;33:2438–45

    Abstract/FREE Full Text
29. 29.
    1. Gage BF,
    2. Cardinalli AB,
    3. Albers GW,
    4. et al

    . Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274:1839–45

    CrossRefPubMedWeb of Science